相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
Gareth J. Morgan et al.
LANCET ONCOLOGY (2011)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
Michael Gnant et al.
LANCET ONCOLOGY (2011)
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study
Giovanni D'Arena et al.
LEUKEMIA & LYMPHOMA (2011)
Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study
Sigurdur Y. Kristinsson et al.
BLOOD (2010)
Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations
Joan Blade et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan et al.
LANCET (2010)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R. A. Kyle et al.
LEUKEMIA (2010)
Plasma Cell Labeling index in the Evaluation of Smoldering (Asymptomatic) Multiple Myeloma
Sumit Madan et al.
MAYO CLINIC PROCEEDINGS (2010)
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
E. Terpos et al.
ANNALS OF ONCOLOGY (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Angela Dispenzieri et al.
BLOOD (2008)
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
Pellegrino Musto et al.
CANCER (2008)
Clinically relevant end points and new drug approvals for myeloma
K. C. Anderson et al.
LEUKEMIA (2008)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
Robert A. Kyle et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy
Deepak Kademani et al.
MAYO CLINIC PROCEEDINGS (2006)
Prevalence of monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect
A Martín et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
